- Conditions
- Locally Advanced or Metastatic Solid Tumours
- Interventions
- AZD0171, Durvalumab, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1273–1296
of 1,904
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- None (Observational study)
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- Durvalumab, Acalabrutinib
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Columbus, Ohio
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Interventions
- AZD4512 monotherapy
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Duarte, California • Jacksonville, Florida • Chicago, Illinois + 3 more
- Conditions
- Relapsed Refractory Multiple Myeloma
- Interventions
- AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib, Pomalidomide
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 48
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Saracatinab, Placebo
- Drug
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Denver, Colorado • New Haven, Connecticut • New York, New York + 1 more
- Conditions
- Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
- Interventions
- Trastuzumab Deruxtecan
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • Basking Ridge, New Jersey + 6 more
- Conditions
- Haematological Malignancies
- Interventions
- AZD0466, Voriconazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more
- Conditions
- Asthma
- Interventions
- AZD4604, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Newport Beach, California + 19 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 31
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 24 more
- Conditions
- Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
- Interventions
- ABT-143, simvastatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 129
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more
- Conditions
- Cancer, Prostate Neoplasms
- Interventions
- goserelin with dutasteride, goserelin with bicalutamide and dutasteride, goserelin with bicalutamide and dutasteride and ketoconazole
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor
- Interventions
- Durvalumab, Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 MG
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Weight Loss
- Interventions
- Dapagliflozin Tablet, Placebo Tablet
- Drug
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Abuse, Substance Dependence
- Interventions
- Quetiapine, Risperidone
- Drug
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Healthy Participants
- Interventions
- AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Type II Diabetes
- Interventions
- AZD1656, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Asthma
- Interventions
- AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more
- Conditions
- RSV Respiratory Syncytial Virus
- Interventions
- AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 3 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment
- Drug · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
- Interventions
- Olaparib, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 20
- States / cities
- Gilbert, Arizona • Orange, California • Stanford, California + 14 more
- Conditions
- Pulmonary/Respiratory Diseases
- Interventions
- Placebo, AZD5634
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Chapel Hill, North Carolina